Microfiber Electrofluidics for Integrated Molecular Diagnostics

Projektinformationen

iMDx

ID Finanzhilfevereinbarung: 715268

DOI 10.3030/715268

Abgeschlossenes Projekt

EK-Unterschriftsdatum 15 Februar 2017

Startdatum 1 August 2017

Enddatum 31 Juli 2022

Finanziert unter

• EXCELLENT SCIENCE - European Research Council (ERC)

Gesamtkosten € 1 499 180,00

EU-Beitrag € 1 499 180,00

Koordiniert durch

KUNGLIGA TEKNISKA HOEGSKOLAN
Sweden

Ziel

"Diagnosis of an increasing number of diseases (such as HIV, Ebola and antibiotic resistant bacteria) rely on centralized laboratories with specialized instruments and skilled personnel. This type of clinical analysis with long lead times and high cost is inappropriate for point of care diagnostics. Portable, automated, and disposable devices with integrated molecular diagnostics (iMDx), could solve this problem. Such devices, however, basically do not exist today.

This research program will develop materials, methods, and diagnostic techniques to enable portable integrated molecular diagnostics (iMDx) devices, that are disposable (almost zero-cost), and that can detect a broad range of diseases using DNA amplification. To achieve this, we will develop ""3D microfiber electrofluidics (MEF)"". MEFs rely on simple and readily available porous sheets including paper, and textiles. Their fabrication is simple, and yet they are very powerful because they can monolithically integrate 3D microfluidics, 3D microelectronics, electrochemical analysis, storage of reagents / biomolecules, as well as handling and manipulation of cells.

We will develop techniques, using the combined capabilities of MEFs, for real-time DNA amplification and electrochemical DNA detection directly from samples. We will use three amplifications techniques for realizing a comprehensive iMDx platform: i) DNA detection, using established and state of the art amplification methods (e.g. PCR, LAMP, RPA). ii) RNA detection, using ""nucleic acid sequence-based amplification"" (NASBA). iii) Protein detection, using antibody to DNA translation through ""proximity ligation assay"" LPA, and using the detection of the amplified DNA is the indirect measure of proteins.

The outcome of this program has the potential to be ground breaking, and change the structure of measuring, processing, and pricing of biomedical information, and dramatically broaden its accessibility and applicability.
"

Wissenschaftliches Gebiet

• natural sciences › biological sciences › genetics › DNA
• medical and health sciences › health sciences › infectious diseases › RNA viruses › ebola
• natural sciences › biological sciences › biochemistry › biomolecules › proteins
• medical and health sciences › health sciences › infectious diseases › RNA viruses › HIV
• medical and health sciences › basic medicine › pharmacology and pharmacy › drug resistance › antibiotic resistance

Programm/Programme

• H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC) Main Programme

Thema/Themen

• ERC-2016-STG - ERC Starting Grant

Aufforderung zur Vorschlagseinreichung

ERC-2016-STG

Finanzierungsplan

ERC-STG - Starting Grant

Gastgebende Einrichtung

KUNGLIGA TEKNISKA HOEGSKOLAN

• Netto-EU-Beitrag: € 1 499 180,00
• Adresse: BRINELLVAGEN 8 ; 100 44 Stockholm ; Schweden
• Region: Östra Sverige › Stockholm › Stockholms län
• Aktivitätstyp: Higher or Secondary Education Establishments
• Gesamtkosten: € 1 499 180,00

Begünstigte (1)

KUNGLIGA TEKNISKA HOEGSKOLAN

Schweden

• Netto-EU-Beitrag: € 1 499 180,00
• Adresse: BRINELLVAGEN 8 ; 100 44 Stockholm
• Region: Östra Sverige › Stockholm › Stockholms län
• Aktivitätstyp: Higher or Secondary Education Establishments
• Gesamtkosten: € 1 499 180,00